fbpx

REQUEST A CONSULTATION

Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.
search
News

Benefits of Combination Immunotherapy for Metastatic Melanoma Patients

Immunotherapy combination can prolong patient lifepsan
According to a recent Sheba study, a combined immunotherapy regimen of Yervoy (Ipilimumab) and Opdivo (Nivolumab) can significantly increase long-term survival rates.

Cancer immunotherapy refers to a variety of treatments that utilize the body’s own immune system to fight the disease. These treatments work in several ways – either by boosting your immune system in general or stimulating your immune system to recognize and attack specific cancer cells. Over the past decade, immunotherapy has become an essential part of treating certain types of cancer.

A long-term study conducted at Sheba Medical Center compared three different metastatic melanoma immunotherapy regimens to determine which is most effective. Participants were divided into groups, the first of which were administered Yervoy (Ipilimumab), the second Opdivo (Nivolumab), and the third a combination of the two.

The study observed metastatic melanoma patients for 6.5 years, and results indicated that patients treated with the combined immunotherapy regimen lived longer: 50% of participants who received the combined regimen survived for six years compared to three among patients treated exclusively with either drug.

While results suggest that for many the most effective treatment is a combined immunotherapy regimen, it is also noted that this is most applicable to older patients (aged 80 or more) or those with milder cases of the malignancy, i.e., a single immunotherapy drug can be quite effective for many other patients.

Related
Sheba and Mayo Clinic merge Data-Sharing Network
News May 18.
Sheba and Mayo Clinic Partner to Transform Patient Care Through an Innovative Data-Sharing Network
Sheba Medical Center has joined the Mayo Clinic Platform Connect, a global data-sharing network that aims to revolutionize healthcare. The groundbreaking platform provides a safe,…
Read More
Sheba Medical Center is working on enhancing patient safety with AI solutions.
News May 18.
Enhancing Patient Safety and Care with AI Solutions
With improving patient care a top priority, Sheba recognized technological innovation as an essential enabler of progress and transformation, with a particular emphasis on artificial…
Read More
IBD passport for patients with ulcerative colitis.
News May 17.
Meet the IBD Passport: A New Hope for Ulcerative Colitis and Crohn’s Disease Patients 
Ulcerative colitis (UC) and Crohn’s disease, the two most common forms of inflammatory bowel disease (IBD), can cause frustrating symptoms like diarrhea, abdominal pain, bloating,…
Read More